← Back to Screener
Lantheus Holdings, Inc (LNTH)
Price$97.13
Value ScoreC
Growth ScoreB
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)69.37%
Price vs S&P 500 (4W)11.17%
VGM Score62.89
Market Capitalization$6.47B
P/E Ratio (Annual)27.68x
All Metrics
P/CF (Annual)16.57x
Book Value / Share (Quarterly)$18.63
P/TBV (Annual)12.02x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)18.13%
Cash Flow / Share (Quarterly)$5.80
Price vs S&P 500 (YTD)38.28%
Gross Margin (TTM)60.48%
Net Profit Margin (TTM)18.05%
EPS (TTM)$4.14
10-Day Avg Trading Volume1.24M
EPS Excl Extra (TTM)$4.14
Revenue Growth (5Y)35.35%
EPS (Annual)$3.41
ROI (Annual)14.08%
Gross Margin (Annual)61.10%
Net Profit Margin (5Y Avg)9.39%
Cash / Share (Quarterly)$7.66
P/E Basic Excl Extra (TTM)23.17x
Revenue Growth QoQ (YoY)1.23%
EPS Growth (5Y)40.71%
P/E Normalized (Annual)27.68x
ROA (Last FY)10.49%
Revenue Growth TTM (YoY)0.62%
EBITD / Share (TTM)$6.34
ROE (5Y Avg)16.22%
Operating Margin (TTM)22.60%
Cash Flow / Share (Annual)$5.48
P/B Ratio5.33x
P/B Ratio (Quarterly)4.07x
Net Income / Employee (Annual)$195,800
EV / Revenue (TTM)4.23x
Net Interest Coverage (TTM)1023.25x
ROA (TTM)12.45%
EPS Growth QoQ (YoY)76.37%
EV / EBITDA (TTM)15.25x
EPS Incl Extra (Annual)$3.41
Current Ratio (Annual)2.70x
Quick Ratio (Quarterly)2.64x
3-Month Avg Trading Volume0.96M
52-Week Price Return31.49%
EV / Free Cash Flow (Annual)18.46x
P/E Incl Extra (TTM)23.17x
Revenue / Employee (TTM)$1,296,000
Tangible BV / Share (Quarterly)$7.78
P/S Ratio (Annual)4.19x
Asset Turnover (Annual)0.69x
52-Week High$103.89
Operating Margin (5Y Avg)13.56%
EPS Excl Extra (Annual)$3.41
CapEx CAGR (5Y)23.62%
Tangible BV CAGR (5Y)21.57%
26-Week Price Return85.30%
Quick Ratio (Annual)2.51x
13-Week Price Return31.65%
Total Debt / Equity (Annual)0.52x
Current Ratio (Quarterly)2.83x
Enterprise Value$6.54B
Revenue / Share Growth (5Y)29.13%
Asset Turnover (TTM)0.69x
Book Value / Share Growth (5Y)17.03%
Revenue / Employee (Annual)$1,292,200
Inventory Turnover (Annual)9.04x
Pretax Margin (Annual)20.35%
Cash / Share (Annual)$5.56
3-Month Return Std Dev42.16%
Gross Margin (5Y Avg)59.21%
Net Income / Employee (TTM)$233,900
EBITDA CAGR (5Y)79.40%
EBITDA Interim CAGR (5Y)46.03%
ROE (Last FY)21.43%
Net Interest Coverage (Annual)34.36x
EPS Basic Excl Extra (Annual)$3.41
P/FCF (TTM)17.14x
Receivables Turnover (TTM)4.39x
EV / Free Cash Flow (TTM)17.33x
Total Debt / Equity (Quarterly)0.47x
EPS Incl Extra (TTM)$4.14
Receivables Turnover (Annual)4.53x
ROI (TTM)16.26%
P/S Ratio (TTM)4.18x
Pretax Margin (5Y Avg)13.07%
Revenue / Share (Annual)$22.52
Tangible BV / Share (Annual)$5.68
Forward P/E17.36x
Free OCF CAGR (5Y)146.38%
Price vs S&P 500 (52W)3.28%
P/E Ratio (TTM)23.17x
EPS Growth TTM (YoY)17.55%
Year-to-Date Return49.21%
5-Day Price Return-3.59%
EPS Normalized (Annual)$3.41
ROA (5Y Avg)7.99%
Net Profit Margin (Annual)15.15%
Month-to-Date Return17.35%
Cash Flow / Share (TTM)$2.32
EBITD / Share (Annual)$5.57
EPS Growth (3Y)104.76%
Operating Margin (Annual)20.16%
LT Debt / Equity (Annual)0.52x
P/CF (TTM)15.86x
ROI (5Y Avg)9.66%
P/E Excl Extra (TTM)23.17x
LT Debt / Equity (Quarterly)0.47x
EPS Basic Excl Extra (TTM)$4.14
P/TBV (Quarterly)9.73x
P/B Ratio (Annual)4.05x
Inventory Turnover (TTM)9.37x
Pretax Margin (TTM)24.17%
Book Value / Share (Annual)$16.87
Price vs S&P 500 (13W)21.90%
Net Margin Growth (5Y)17.41%
Beta-0.02x
P/FCF (Annual)18.26x
Revenue / Share (TTM)$23.51
ROE (TTM)24.33%
52-Week Low$47.25
vGradeC
gGradeB
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 261.46est. 1.26
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.05
4.11
4.11
4.11
Industry Peers — In Vitro Diagnostics(18)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LNTHLantheus Holdings, Inc | C | B | B | $97.13 |
| IDXXIdexx Laboratories Inc | D | B | C | $566.79 |
| NNNNAnbio Biotechnology Class A Ordinary Shares | F | B | A | $30.17 |
| CLDXCelldex Therapeutics, Inc | F | F | B | $30.14 |
| NTLAIntellia Therapeutics, Inc | D | C | B | $13.73 |
| NEOGNeogen Corp | C | C | C | $8.92 |
| QDELQuidelOrtho Corporation Common Stock | B | C | D | $13.27 |
| ACHVAchieve Life Sciences, Inc. | F | F | B | $5.30 |
| MYGNMyriad Genetics Inc | C | C | D | $4.28 |
| TKNOAlpha Teknova, Inc. Common Stock | C | C | B | $5.37 |
| IMDXInsight Molecular Diagnostics Inc. Common Stock | F | D | B | $6.16 |
About
Lantheus Holdings is a radiopharmaceutical company that develops and markets imaging agents and diagnostic solutions focused on oncology and precision diagnostics. Its products are used by physicians and technologists in clinical settings to identify and monitor disease. The company operates primarily in the United States, with international distribution networks in Europe, Canada, Australia, Asia-Pacific, and Latin America.